Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077149 | 0.98 | KDM4E (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2075399 | 0.98 | KDM4E (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL21074178 | 0.94 | LTA4H (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1573576 | 0.91 | USP2 (0.50) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15884868 | 0.88 | ALDH1A1 (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6186091 | 0.86 | KDM4E (0.52) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10868169 | 0.85 | ALDH1A1 (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10554729 | 0.83 | KDM4E (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL13187900 | 0.83 | ALDH1A1 (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL13187873 | 0.83 | ALDH1A1 (0.43) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3814356-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2021-05-05 | — | — | EP | disclosed |
| CN-111051309-A | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019233458-A1 | VEGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-7560481-B2 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090149501-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1833824-A1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBVIE INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2006069196-A1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2006-06-29 | — | — | WO | disclosed |
| CN-1119344-C | Heterocyclic substed. pyrrolidine amide derivs. | AVENTIS PHARMA INC (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1098259-C | Novel carboxy-substituted cyclic carboxamide derivatives | AVENTIS PHARMA INC (US) | 2003-01-08 | — | — | CN | disclosed |
| US-5811439-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS | SENGA PHARMACEUTICAL LABORATORY INC. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0780389-A1 | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0178946-A2 | 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149501-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | CNR2, CNR1, OPRL1 | KDM4E 2579/4885USP2 3708/4885ALDH1A1 1568/4885 |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | CNR2, CNR1, TRPV1 | KDM4E 3554/4885USP2 3924/4885ALDH1A1 1901/4885 |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | KDM4E 3952/4885USP2 3328/4885ALDH1A1 571/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | KDM4E 3952/4885USP2 3328/4885ALDH1A1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.